Compare Ally Financial Inc (ALLY) vs Hims and Hers Health Inc (HIMS) Price & Performance

Ally Financial (ALLY) trades at $43.79, showing modest daily gains of 0.16%. The stock presents a compelling valuation with a P/E of 10.34 and P/B of 0.99, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations despite revenue growth, while technical indicators show bearish momentum with the stock trading near key support levels. The company maintains strong institutional support with 68% analyst buy ratings and recently declared a $0.30 dividend.

Ally offers value investment potential with attractive valuation metrics and solid dividend yield, though near-term headwinds include recent earnings miss and bearish technical signals. The auto finance business faces credit risk concerns amid economic uncertainty, but long-term digital banking leadership and improving margins provide growth catalysts. Upside potential exists if the company can maintain credit quality while expanding its digital banking footprint.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.